Send to

Choose Destination
Cardiovasc Drugs Ther. 2016 Feb;30(1):13-8. doi: 10.1007/s10557-016-6656-3.

Identifying new Risk Markers and Potential Targets: The Value of the Proteome.

Author information

National Institute for Health and Medical Research (INSERM), Research Unit 1166 ICAN, University of Pierre and Marie Curie - Paris 6, Pitié - Salpétrière University Hospital, 91, boulevard de l'Hôpital, 75013, Paris, France.


Several protein biomarkers, including cardiac troponin T, cardiac troponin I, B-type natriuretic peptide, C-reactive protein and apolipoprotein A-I, are widely employed in the evaluation of cardiovascular disease. Several of such potential biomarkers, or their multiscores, have been assessed over the last years for the prediction of cardiovascular risk but only a few of them have been validated for clinical use. Substantial improvement in the cardiovascular risk prediction and reclassification relative to traditional models therefore remains a difficult task presently unresolved. Hence, a potential importance of alternative approaches which may rely on novel proteomic biomarkers among others. Plasma or serum concentrations of numerous proteins were measured using proteomic approaches to establish their relationships with cardiovascular disease; none of them was however evaluated for cardiovascular risk prediction and subject stratification in rigorous large-scale studies. Thus, further research is needed to identify novel candidates that can improve cardiovascular risk prediction, subject stratification and standard care. Proteomics will undoubtedly remain a key approach to address this major clinical and scientific challenge.


Biomarkers; Cardiovascular disease; Proteomics

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center